Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: LTK007 who wrote (1590)	2/11/1999 10:51:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 2135

A lot of science is more art than science and I suspect that the Boston group was just more familiar with the handling of the protein. ENMD still has many hurdles, but the inability of the NCI to replicate the results was one uncertainty that is gone. From what I heard of Holaday on CNBC, it sounded like angostatin quantity issues would be solved with the same expression vectors used to generate endostatin. Tomorrow morning's price movement however won't be based on science. It will again be dictated by press coverage and today's rebound.